Literature DB >> 3681315

Proximal weakness of the extremities as main feature of amyloid myopathy.

F G Jennekens1, J H Wokke.   

Abstract

Two patients with muscle weakness caused by amyloid myopathy are described. Characteristic features such as pseudohypertrophy and abnormal firmness, and tumours of muscles were absent. It is suggested that muscle weakness in amyloid myopathy is caused by layers of amyloid covering muscle fibres. In middle aged or elderly patients with proximal muscle weakness the diagnosis of amyloid myopathy should be considered.

Entities:  

Mesh:

Year:  1987        PMID: 3681315      PMCID: PMC1032464          DOI: 10.1136/jnnp.50.10.1353

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  12 in total

1.  Primary amyloidosis.

Authors:  J H FISHER
Journal:  Can Med Assoc J       Date:  1958-02-15       Impact factor: 8.262

2.  Skeletal muscle pseudohypertrophy in primary amyloidosis.

Authors:  J N Whitaker; K Hashimoto; M Quinones
Journal:  Neurology       Date:  1977-01       Impact factor: 9.910

3.  Characterization of amyloid deposits in biopsies of 15 with "sporadic" (non-familial or plasma cell dyscrasia amyloid polyneuropathy.

Authors:  M C Dalakas; G Cunningham
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

4.  Primary amyloidosis of muscle.

Authors:  R K Lange
Journal:  South Med J       Date:  1970-03       Impact factor: 0.954

5.  [Sporadic, generalized pseudo-myopathy in primary endomysial vascular amyloidosis].

Authors:  J J Martin; L Van Bogaert; J Van Damme; J Peremans
Journal:  J Neurol Sci       Date:  1970-08       Impact factor: 3.181

6.  The light and electron microscopic autoradiographic demonstration of local amyloid formation in spleen explants.

Authors:  A S Cohen; E Gross; T Shirahama
Journal:  Am J Pathol       Date:  1965-12       Impact factor: 4.307

7.  Evidence for vesicular transport of horseradish peroxidase across endoneurial vessels of the sciatic nerve in normal mice.

Authors:  B Arvidson
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

8.  Myopathy associated with amyloid angiopathy.

Authors:  J Bruni; J M Bilbao; P H Pritzker
Journal:  Can J Neurol Sci       Date:  1977-02       Impact factor: 2.104

9.  Clinical significance of histopathologic patterns of cardiac amyloidosis.

Authors:  T J Smith; R A Kyle; J T Lie
Journal:  Mayo Clin Proc       Date:  1984-08       Impact factor: 7.616

Review 10.  Amyloidosis (AL). Clinical and laboratory features in 229 cases.

Authors:  R A Kyle; P R Greipp
Journal:  Mayo Clin Proc       Date:  1983-10       Impact factor: 7.616

View more
  6 in total

1.  Isolated myopathy as the initial manifestation of primary systemic amyloidosis.

Authors:  D Karacostas; M Soumpourou; I Mavromatis; G Karkavelas; I Poulios; I Milonas
Journal:  J Neurol       Date:  2005-03-08       Impact factor: 4.849

2.  Lymphoma, paraproteinaemia, and neuropathy.

Authors:  J H Wokke; J H Morris; M Donaghy
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

3.  Myopathy in primary systemic amyloidosis.

Authors:  M A Gertz; R A Kyle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

4.  Amyloid myopathy presenting with respiratory failure.

Authors:  J Ashe; C O Borel; G Hart; R L Humphrey; D A Derrick; R W Kuncl
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-02       Impact factor: 10.154

5.  Chronic myopathy due to immunoglobulin light chain amyloidosis.

Authors:  Irini Manoli; Justin Y Kwan; Qian Wang; Elisabeth J Rushing; Maria Tsokos; Andrew E Arai; Warner M Burch; Angela Dispenzieri; Alexandra C McPherron; William A Gahl
Journal:  Mol Genet Metab       Date:  2013-02-04       Impact factor: 4.797

6.  Muscle involvement with pseudohypertrophy in systemic light chain amyloidosis: Case report.

Authors:  Mirela Draghici; Andreea Jercan; Sorina Nicoleta Badelita; Ruxandra Maria Irimia; Alexandra Eugenia Bastian; Camelia Dobrea; Monica Popescu; Daniel Coriu
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.